Compare Cassava Sciences Inc (FLNA) vs HP Inc (HPQ) Price & Performance

FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.

While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.

HPQ trades at $30.2, down 6.33% on the day, amid concerns over a projected mid-single-digit PC sales decline in 2027. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels are mixed. Fundamentally, HPQ maintains solid profitability with a 4.14% net margin and attractive valuation at a P/E of 12.38 and P/S of 0.51. Recent earnings beats highlight operational strength, but negative shareholder equity and high liabilities pose balance sheet risks.

The outlook is cautious; while HPQ's dividend yield of 3.82% and consistent cash flow provide income appeal, near-term headwinds from PC market softness and competitive pressures may limit upside. Analyst consensus is mixed with a $25.75 price target below current levels, suggesting limited near-term growth potential. Investors should weigh stable cash generation against cyclical industry risks and elevated debt.